FDA panel evaluates MDMA therapy for post-traumatic stress disorder
The Food and Drug Administration is considering whether to approve the use of MDMA, also known as Ecstasy, to treat post-traumatic stress disorder. An independent advisory group of experts will review the studies on Tuesday and is expected to vote on whether the treatment is effective and whether its benefits outweigh its risks.The commission will hear from Lykos Therapeutics, which presented evidence from clinical trials in an effort to get the agency's approval to legally sell the drug to treat people with a combination of MDMA and talk therapy.Millions of Americans suffer from PTSD, including military veterans at high risk for suicide. No new treatments for PTSD have been approved in more than 20 years.What is MDMA?Methylenedioxymethamphetamine (MDMA) is a synthetic psychoactive d...